Verapamil and Lithium in Maintenance Therapy of Manic Patients

Giannini, A. James; Taraszewski, Robert; Loiselle, Robert H.

doi:10.1002/j.1552-4604.1987.tb05600.x

Cited by 40 publications

(19 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The freedom from cardiovascular side effects with verapamil as seen in the electrocardiographic parameters in this study is in agreement with available literature. Gianni et al, in single blind placebo control crossover study of 30 d did not report any cardiovascular side effects with verapamil [7].…”

Section: Discussionmentioning

confidence: 93%

See 1 more Smart Citation

Comparative Study of Electrocardiographic Changes in Patients of Acute Mania Receiving Verapamil or Lithium Carbonate

Singh

Kaur

Sehgal

2014

JCDR

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 93%

“…Verapamil is effective for both shortterm and long-term treatment [6,7]. Verapamil have a synergistic effect with lithium on the severity of bradycardia.…”

mentioning

confidence: 99%

Comparative Study of Electrocardiographic Changes in Patients of Acute Mania Receiving Verapamil or Lithium Carbonate

Singh

Kaur

Sehgal

2014

JCDR

View full text Add to dashboard Cite

“…Considering only reports with a sample size of three or more subjects, we could identify 27 studies published so far examining the efficacy of calcium-channel blockers for mood disorders as summarized in Tables IIa and IIb [Caillard and Masse, 1982;Giannini et al, 1984Giannini et al, , 1985Giannini et al, , 1987Goldstein, 1984;Brotman et al, 1986;Dose et al, 1986;Dubovsky et al, 1986Dubovsky et al, , 2001Barton and Gitlin, 1987;Dinan et al, 1988;Kramer et al, 1988;Mathis et al, 1988;Hoschl and Kozeny, 1989;Brunet et al, 1990;De Beaurepaire, 1992;Garza-Trevino et al, 1992;Goodnick, 1993;Pazzaglia et al, 1993;Lenzi et al, 1995;Walden et al, 1995;Walton et al, 1996;Janicak et al, 1998;Pazzaglia et al, 1998;Silverstone and Birkett, 2000;Wisner et al, 2002;Taragano et al, 2005]. Of these, 14 were single or double-blind controlled studies (eight with a crossover design), 7 were open trials, and 6 were case series.…”

Section: Clinical Investigationmentioning

confidence: 99%

L‐type calcium channels and psychiatric disorders: A brief review

Casamassima

Hay

Benedetti

et al. 2010

American J of Med Genetics Pt B

116

View full text Add to dashboard Cite

Emerging evidence from genome-wide association studies (GWAS) support the association of polymorphisms in the alpha 1C subunit of the L-type voltage-gated calcium channel gene (CACNA1C) with bipolar disorder. These studies extend a rich prior literature implicating dysfunction of L-type calcium channels (LTCCs) in the pathophysiology of neuropsychiatric disorders. Moreover, calcium channel blockers reduce Ca(2+) flux by binding to the α1 subunit of the LTCC and are used extensively for treating hypertension, preventing angina, cardiac arrhythmias and stroke. Calcium channel blockers have also been studied clinically in psychiatric conditions such as mood disorders and substance abuse/dependence, yielding conflicting results. In this review, we begin with a summary of LTCC pharmacology. For each category of disorder, this article then provides a review of animal and human data. In particular, we extensively focus on animal models of depression and clinical trials in mood disorders and substance abuse/dependence. Through examining rationale and study design of published clinical trials, we provide some of the possible reasons why we still do not have definitive evidence of efficacy of calcium-channel antagonists for mood disorders. Refinement of genetic results and target phenotypes, enrollment of adequate sample sizes in clinical trials and progress in physiologic and pharmacologic studies to synthesize tissue and isoform specific calcium channel antagonists, are all future challenges of research in this promising field. © 2010 Wiley-Liss, Inc.

show abstract

“…Tiabagina Tiabagina Tiabagina Tiabagina Tiabagina -Tiabagina pode ser uma droga útil como terapia adjuntiva do transtorno bipolar, continuando ser eficaz por diversos meses (Schaffer e Schaffer, 1999 (Giannini et al 1987). …”

Section: Outras Drogasunclassified

Tratamento do transtorno bipolar: eutimia

Souza¹

2005

Rev. psiquiatr. clín.

View full text Add to dashboard Cite

ResumoO transtorno bipolar é um quadro complexo caracterizado por episódios de depressão, mania ou hipomania e fases assintomáticas. O tratamento visa ao controle de episódios agudos e prevenção de novos episódios. O tratamento farmacológico iniciou-se com o lítio. Até o momento, o lítio permanece como o tratamento com mais evidências favoráveis na fase de manutenção. Outros tratamentos demonstram eficácia nessa fase, como o valproato, a carbamazepina e os antipsicóticos atípicos. Dos antipsicóticos atípicos o mais estudado nesta fase do tratamento é a olanzapina. Mais estudos prospectivos são necessários para confirmar a ação profilática de novos agentes.Palavras-chave: Transtorno bipolar, manutenção, estabilizadores do humor. AbstractBipolar disorder is a complex disorder characterized by depression episodes, mania or hypomania and asymptomatic phases. The treatment aims at the control of acute episodes and prevention of new episodes. The pharmacological treatment was inaugurated with lithium. Until the moment, lithium remains as the treatment with more favorable evidences in the maintenance phase. Other treatments demonstrate efficacy in this phase, as valproate, carbamazepine and atypical antipsychotics. Of the atypical antipsychotics, the most studied in this phase of treatment is olanzapine. More prospective studies are necessary to confirm prophylactic action of new agents.Key words: Bipolar disorder, maintenance, mood stabilizers. Recebido: 17/11/2004 -Aceito: 07/01/2005 O transtorno bipolar é um transtorno crônico e complexo caracterizado por episódios de depressão, mania ou hipomania de forma isolada ou mista com grande morbidade e mortalidade. O tratamento do paciente eutímico deve sempre considerar a possibilidade de o paciente vir a ter episódios de mania e/ou depressão. A eutimia, usualmente, é definida como a remissão dos sintomas, entretanto, idealmente, seria o período no qual o paciente não apenas estaria sem sintomas, mas (re)integrado funcionalmente em suas atividades de rotina. O objetivo do tratamento, portanto, é manter o paciente sem sintomas. Assim, a meta principal do tratamento é a remissão e não apenas a resposta clínica (redução de 50% dos sintomas observados), que

show abstract

Verapamil and Lithium in Maintenance Therapy of Manic Patients

Cited by 40 publications

References 13 publications

Comparative Study of Electrocardiographic Changes in Patients of Acute Mania Receiving Verapamil or Lithium Carbonate

Comparative Study of Electrocardiographic Changes in Patients of Acute Mania Receiving Verapamil or Lithium Carbonate

L‐type calcium channels and psychiatric disorders: A brief review

Tratamento do transtorno bipolar: eutimia

Contact Info

Product

Resources

About